- Oops!Something went wrong.Please try again later.
BREA, Calif., May 17, 2022 /PRNewswire/ -- Envista Holdings Corporation (NYSE: NVST) ("Envista") today announced it has entered into a definitive agreement to acquire Osteogenics Biomedical Inc, Allotech LLC and OBI Biologics, Inc (together "Osteogenics"). The transaction is subject to customary regulatory approvals and expected to close in the Third Quarter.
Osteogenics is a leader in the development of innovative regenerative solutions for periodontists, oral & maxillofacial surgeons, and clinicians involved in implant dentistry throughout the world. Primarily sold under the CytoplastTM brand name, Osteogenics offers a complete line of bone grafting products. Bone grafting and regenerative therapies are often a critical step in implant based tooth replacements. By improving bone stability, regenerative solutions support better clinical outcomes for more patients.
Envista's CEO Amir Aghdaei said, "Increasing our capabilities in regenerative solutions is consistent with our intention to digitize, personalize, and democratize oral care. Osteogenics is a recognized pioneer in membrane technologies used in dental bone grafting procedures. They are a trusted brand and have a proven track record of growth. We are excited to welcome the Osteogenics team to Envista."
The transaction is not subject to a financing condition or shareholder vote.
Envista is a global family of more than 30 trusted dental brands, including Nobel Biocare, Ormco, DEXIS, and Kerr united by a shared purpose: to partner with professionals to improve lives. Envista helps its customers deliver the best possible patient care through industry-leading dental consumables, solutions, technology, and services. Our comprehensive portfolio, including dental implants and treatment options, orthodontics, and digital imaging technologies, covers a wide range of dentists' clinical needs for diagnosing, treating, and preventing dental conditions as well as improving the aesthetics of the human smile. With a foundation comprised of the proven Envista Business System (EBS) methodology, an experienced leadership team, and a strong culture grounded in continuous improvement, commitment to innovation, and deep customer focus, Envista is well equipped to meet the end-to-end needs of dental professionals worldwide. Envista is one of the largest global dental products companies, with significant market positions in some of the most attractive segments of the dental products industry. For more information, please visit www.envistaco.com.
Certain statements in this press release are "forward-looking" statements within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the impact of the COVID-19 pandemic, including new variants of the virus, the pace of recovery in the markets in which we operate, global supply chain disruptions and potential staffing shortages, the conditions in the U.S. and global economy, the markets served by us and the financial markets, the impact of our debt obligations on our operations and liquidity, developments and uncertainties in trade policies and regulations, contractions or growth rates and cyclicality of markets we serve, the effect of the Osteogenics acquisition on our business relationships, operating results, share price or business generally, the failure to realize the expected benefits from the Osteogenics acquisition, fluctuations in inventory of our distributors and customers, loss of a key distributor, our relationships with and the performance of our channel partners, competition, our ability to develop and successfully market new products and services, the potential for improper conduct by our employees, agents or business partners, our compliance with applicable laws and regulations (including regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof, penalties associated with any off-label marketing of our products, modifications to our products that require new marketing clearances or authorizations, our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments, our ability to integrate the businesses we acquire and achieve the anticipated benefits of such acquisitions, contingent liabilities relating to acquisitions, investments and divestitures, security breaches or other disruptions of our information technology systems or violations of data privacy laws, our ability to adequately protect our intellectual property, the impact of our restructuring activities on our ability to grow, risks relating to currency exchange rates, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities including intellectual property and environmental, health and safety matters, risks relating to product, service or software defects, risks relating to product manufacturing, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole or limited sources of supply, the impact of regulation on demand for our products and services, labor matters, international economic, political, legal, compliance and business factors, and disruptions relating to war, terrorism, climate change, widespread protests and civil unrest, man-made and natural disasters, public health issues and other events. Additional information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our Annual Report on Form 10-K for fiscal year 2021 and our Quarterly reports on Form 10-Q. These forward-looking statements speak only as of the date of this press release and except to the extent required by applicable law, we do not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.
Envista Holdings Corporation
200 S. Kraemer Blvd., Building E
Brea, CA 92821
Telephone: (714) 817-7000
Fax: (714) 817-5450
View original content to download multimedia:https://www.prnewswire.com/news-releases/envista-to-acquire-osteogenics-biomedical-business-301549633.html
SOURCE Envista Holdings Corporation